Minoru Kanaya, Masahiro Onozawa, Toshihiro Matsukawa, Naoki Miyashita, Fumiaki Fujii, Shota Yoshida, Jun Nagai, Masayuki Aiba, Daisuke Hidaka, Junichi Hashiguchi, et al. Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood cancer journal. 2025. 15. 1. 118-118
Naoki Miyashita, Masahiro Onozawa, Kohei Kasahara, Toshihiro Matsukawa, Yasuhito Onodera, Kohjin Suzuki, Tomoiku Takaku, Takanori Teshima, Takeshi Kondo. CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway. Cancer science. 2025
N. Miyashita, M. Onozawa, K. Hayasaka, S. Kunishima, T. Teshima. NOVEL HETEROZYGOUS ITGB3 P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN AIIBB3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL AIIBB3 LOCALIZATION. HAEMATOLOGICA. 2017. 102. 122-122
